Journal
NEUROLOGICAL RESEARCH
Volume 41, Issue 5, Pages 480-487Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/01616412.2019.1580455
Keywords
Moyamoya disease; adult; cognition; antiplatelet drug
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology of Japan [S1491001]
- Japan Society for the Promotion of Science [JP18K09002]
- Nihon Medi-Physics Co., Ltd.
Ask authors/readers for more resources
Objective: Adult patients with ischemic moyamoya disease (MMD) who receive treatment with antiplatelet drugs reportedly show improvements in neuropsychological test scores after around 2 years. The purpose of the present study subanalyzing the same patient cohort used in a previous study was to determine which antiplatelet drug, clopidogrel or cilostazol, results in better improvement of cognitive function among non-surgical adult patients showing ischemic MMD without severe hemodynamic compromise. Methods: Sixty-six patients without cerebral misery perfusion on O-15 gas positron emission tomography were treated with pharmacotherapy alone. Patients >= 50 years old and <50 years old initially received clopidogrel and cilostazol, respectively. Any patient suffering side effects of the antiplatelet drug switched to the other antiplatelet drug. Neuropsychological tests were performed at study entry and at the end of the 2-year follow-up, and differences in each neuropsychological test score between the two time points (second test score - first test score) were calculated and defined as Delta scores. Results: Among the five neuropsychological tests, Delta scores for two tests were significantly greater in patients treated with cilostazol (n = 36) than in those treated with clopidogrel (n = 30), and Delta scores of the remaining three tests did not differ between patient groups. Based on Delta scores, 15 patients (23%) were defined as showing interval cognitive improvement. On multivariate analysis, cilostazol administration (95% confidence interval, 1.19-193.98; P = 0.0361) represented an independent predictor of interval cognitive improvement. Conclusions: Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic MMD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available